A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Subjects With Phenylketonuria

Trial Profile

A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Subjects With Phenylketonuria

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Feb 2016

At a glance

  • Drugs Sapropterin (Primary)
  • Indications Phenylketonuria
  • Focus Therapeutic Use
  • Acronyms PKU-Ascend
  • Sponsors BioMarin Pharmaceutical
  • Most Recent Events

    • 30 Mar 2015 According to a BioMarin media release, results of a post-hoc sub-analysis of this study were presented at the 2015 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2015.
    • 30 Mar 2015 Results published in a BioMarin media release.
    • 15 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top